HURATuHURA BIOSCIENCES, INC./NV
This is the year TuHURA Biosciences has to prove it’s not just another biotech vaporware story — the next catalyst is the Phase 2 top-line results on 2026-11-02, which will anchor the stock at $2.14 and set the stage for either a bull run to $2.65 or a bear retreat to $1.95, with a 47% lean toward the bear. The company’s survival hinges on whether it can deliver the data that turns its clinical pipeline from a speculative bet into a real-world therapy. If it fails, the stock could fall back to $1.95, but if it succeeds, the market might start to take the company seriously — and the price could climb to $2.65. Either way, the next few months are a make-or-break test for HURA.
The Read
4% following positive corporate updates and leadership hires, dipped 20.
The schedule
- Fri13Nov
Quarterly earnings report and guidance for Q3 2026, with potential impact on investor sentiment and stock price.
- Fri12Feb
- Fri14May
Past
- Mon14Sep
Company presentation event with potential updates on clinical progress and strategic initiatives.
- Mon15Jun
Actual outcome: Bull · $2.30 at outcome
HURA filed an IND for TBS-2025 in AML and blood cancers, with FDA providing written feedback. Positive regulatory clarity and development pathway validation drove a 107% surge. The FDA's alignment with proposed Pha pathways signaled near-term progress. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +107.1% from 2026-04-02 to 2026-08-13 (~4.2σ vs typical 10d vol). Target date 2026-07-02 reached; move through 2026-08-13 observed. Confidence 95%.
HURA filed an IND for TBS-2025 in AML and blood cancers, with FDA providing written feedback. Positive regulatory clarity and development pathway validation drove a 107% surge. The FDA's alignment with proposed Pha pathways signaled near-term progress. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +107.1% from 2026-04-02 to 2026-08-13 (~4.2σ vs typical 10d vol). Target date 2026-07-02 reached; move through 2026-08-13 observed. Confidence 95%.
- Fri15May
Actual outcome: Bull · $2.50 at outcome
TuHURA reported Q1 2026 EPS of -$0.13, perfectly matching analyst estimates, alongside a broader corporate update. The in-line financial results and updated corporate outlook reassured investors regarding the company's cash runway and Phase 3 clinical progress, driving an 8.2% rally in the stock.
- Wed22Apr
Actual outcome: Bull · $2.13 at outcome
TuHURA Biosciences announced a $50M credit facility on April 22, 2026, providing liquidity for clinical trials and operations. This capital raise signaled strong investor confidence in the company's pipeline and strategic execution, driving a sharp short-term rally. The funding directly supported key development milestones, including the IND filing later in Q2. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +107.1% from 2026-04-02 to 2026-08-07 (~4.2σ vs typical 10d vol). Target date 2026-05-10 reached; move through 2026-08-07 observed. Confidence 95%.
TuHURA Biosciences announced a $50M credit facility on April 22, 2026, providing liquidity for clinical trials and operations. This capital raise signaled strong investor confidence in the company's pipeline and strategic execution, driving a sharp short-term rally. The funding directly supported key development milestones, including the IND filing later in Q2. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +107.1% from 2026-04-02 to 2026-08-07 (~4.2σ vs typical 10d vol). Target date 2026-05-10 reached; move through 2026-08-07 observed. Confidence 95%.
- Mon20Apr
Actual outcome: Bear · $2.22 at outcome
TuHURA did not announce the expected clinical data abstract acceptance, instead revealing a $50 million credit facility and royalty transaction to extend its cash runway into 2028. The absence of the anticipated clinical catalyst and potential concerns over the new financing obligations led to a sell-off, driving the stock below the $2.40 bear floor.
- Mon30Mar
Actual outcome: Bull · $1.45 at outcome
Although the stock initially dipped following the company's Q4 and full-year 2025 financial results, it rebounded strongly as TuHURA provided positive corporate updates and bolstered its clinical leadership team. The strategic appointments of industry veterans to lead clinical operations and the VISTA program signaled strong progress toward Phase 3 trials, ultimately driving the stock well above the bull target.
- Sun15Mar
Actual outcome: Bull · $1.88 at outcome
TuHURA Biosciences announced the strategic appointment of Dr. Craig Tendler, the former Global Head of Oncology Clinical Development at Johnson & Johnson, to lead its VISTA program for acute myeloid leukemia and other blood cancers. The stock reacted positively to this development, as Dr. Tendler brings over 29 years of drug development experience and a track record of securing more than 30 oncology regulatory approvals, significantly boosting investor confidence in the company's clinical pipeline.
